Putting the Dough in the Donut Hole: Big Pharma Hits the Sweet Spot in the Reform Debate
This article was originally published in RPM Report
Executive Summary
It's not often than any industry group voluntarily agrees to give up $80 billion in future revenues, but that's what the Pharmaceutical Research & Manufacturers of America is pledging to do to in the context of the health care reform debate. There are a lot of details to work out, but this is a case where what is important is not what PhRMA is giving-but what it gets.
You may also be interested in...
Clinton Transition Team Includes Tanden, Underscoring Rx Pricing Focus
Center for American Progress President Neera Tanden has actively advocated Clinton’s position on prescription drug price controls over the past year.
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?